These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 29381220)
1. Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System. Eser A; Primas C; Reinisch S; Vogelsang H; Novacek G; Mould DR; Reinisch W J Clin Pharmacol; 2018 Jun; 58(6):790-802. PubMed ID: 29381220 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients. Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008 [TBL] [Abstract][Full Text] [Related]
3. Personalized Dosing of Infliximab in Patients With Inflammatory Bowel Disease Using a Bayesian Approach: A Next Step in Therapeutic Drug Monitoring. Desai DC; Dherai AJ; Strik A; Mould DR J Clin Pharmacol; 2023 Apr; 63(4):480-489. PubMed ID: 36458468 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313 [TBL] [Abstract][Full Text] [Related]
12. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852 [TBL] [Abstract][Full Text] [Related]
13. Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. Ternant D; Passot C; Aubourg A; Goupille P; Desvignes C; Picon L; Lecomte T; Mulleman D; Paintaud G Clin Pharmacokinet; 2018 Sep; 57(9):1173-1184. PubMed ID: 29236229 [TBL] [Abstract][Full Text] [Related]
14. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Xiong Y; Mizuno T; Colman R; Hyams J; Noe JD; Boyle B; Tsai YT; Dong M; Jackson K; Punt N; Rosen MJ; Denson LA; Vinks AA; Minar P Clin Pharmacol Ther; 2021 Jun; 109(6):1639-1647. PubMed ID: 33354765 [TBL] [Abstract][Full Text] [Related]
15. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486 [TBL] [Abstract][Full Text] [Related]
17. Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Malíčková K; Ďuricová D; Bortlík M; Hind'oš M; Machková N; Hrubá V; Lukáš M; Zima T; Lukáš M Biologicals; 2016 Jan; 44(1):33-6. PubMed ID: 26603635 [TBL] [Abstract][Full Text] [Related]
18. Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease. Frymoyer A; Hoekman DR; Piester TL; de Meij TG; Hummel TZ; Benninga MA; Kindermann A; Park KT J Pediatr Gastroenterol Nutr; 2017 Dec; 65(6):639-645. PubMed ID: 28471911 [TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807 [TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Hemperly A; Vande Casteele N Clin Pharmacokinet; 2018 Aug; 57(8):929-942. PubMed ID: 29330783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]